Durvalumab
Based on 6 publication(s) in Google Scholar
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.60%
- CAS No.: 1428935-60-7
- 분자량:146.32 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Durvalumab
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Biological Activity
Human IgG1 (L234F/L235E/P331S) kappa
Human
B7-H1/PD-L1/CD274
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mice with HPAC tumor, following coimplantation of primary human T cells; NOD/SCID mice with A375 tumor, following coimplantation of primary human T cells[2]
-
Dosage:5, 1, 0.1, and 0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5, 1, and 0.1 mg/kg for NOD/SCID mice with A375 tumor
-
Administration:Administration i.p.; twice per week; for 3 weeks
-
Result:Significantly inhibited the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1428935-60-7
-
Appearance Liquid
-
분자량 146.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Durvalumab]
-
Synonyms
MEDI 4736
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers. [Abstract]2020 Dec;10(12):1872-1893. PMID: 32938586
Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]
4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. The tumor growth was monitored twice per week. n=8 mice per group.
Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]
Survival curve of the mice of the combination of Cam, NGI-1 nanoparticle and Durvalumab (5 mg/kg, i.p., 3 times). n=8 mice per group.
Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]
4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. Tumor tissues were subjected to the immunohistochemically staining with anti-CD8 antibody.
-
Cell Rep
PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II. [Abstract]2022 Feb 8;38(6):110349. PMID: 35139382 -
Biochem Genet
Cuproptosis-Related Gene FDX1 Induces Malignant Progression and Immune Suppression in Triple-Negative Breast Cancer. [Abstract]2025 Sep 5. PMID: 40911146 -
-
Durvalumab purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.
Migration-focused results of ECIS tests on T98G and U87 glioblastoma cells treated with Radiation and Durvalumab. Representative plot of normalized resistance in the first 40 hours posttreatment for T98G.
Durvalumab purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.
Barrier function-focused results of ECIS tests on T98G glioblastoma cells treated with radiation and durvalumab. Representative plot of the barrier function Rb posttreatment for T98G shown.
-
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62. [Content Brief]
[2]. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz